BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9389932)

  • 1. Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells.
    Moreland N; Finlay GJ; Dragunow M; Holdaway KM; Baguley BC
    Eur J Cancer; 1997 Sep; 33(10):1668-76. PubMed ID: 9389932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
    Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
    Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine.
    Baguley BC; Leteurtre F; Riou JF; Finlay GJ; Pommier Y
    Eur J Cancer; 1997 Feb; 33(2):272-9. PubMed ID: 9135499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.
    Finlay GJ; Holdaway KM; Baguley BC
    Cancer Chemother Pharmacol; 1994; 34(2):159-65. PubMed ID: 8194167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
    Deptala A; Li X; Bedner E; Cheng W; Traganos F; Darzynkiewicz Z
    Int J Oncol; 1999 Nov; 15(5):861-71. PubMed ID: 10536167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors.
    Giuliano M; Lauricella M; Vassallo E; Carabillò M; Vento R; Tesoriere G
    Invest Ophthalmol Vis Sci; 1998 Jul; 39(8):1300-11. PubMed ID: 9660477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
    Haldane A; Finlay GJ; Baguley BC
    Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
    Leontiou C; Lakey JH; Austin CA
    Mol Pharmacol; 2004 Sep; 66(3):430-9. PubMed ID: 15322234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of p53 induces M-phase retardation following G2 DNA damage checkpoint abrogation.
    Minemoto Y; Uchida S; Ohtsubo M; Shimura M; Sasagawa T; Hirata M; Nakagama H; Ishizaka Y; Yamashita K
    Arch Biochem Biophys; 2003 Apr; 412(1):13-9. PubMed ID: 12646262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin.
    Jaks V; Jõers A; Kristjuhan A; Maimets T
    Oncogene; 2001 Mar; 20(10):1212-9. PubMed ID: 11313865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
    Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
    Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
    D'Arpa P; Beardmore C; Liu LF
    Cancer Res; 1990 Nov; 50(21):6919-24. PubMed ID: 1698546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.
    Haldane A; Holdaway KM; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1993; 32(6):463-70. PubMed ID: 8258195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic action and cell cycle effects of ALGA, a peptidic derivative of the antileukemic drug amsacrine.
    Collyn-d'Hooghe M; Bernier JL; Henichart JP
    Cancer Biochem Biophys; 1987 Sep; 9(3):257-64. PubMed ID: 3435897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest.
    Wesierska-Gadek J; Schloffer D; Gueorguieva M; Uhl M; Skladanowski A
    Cancer Res; 2004 Jul; 64(13):4487-97. PubMed ID: 15231658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C; Covey JM; Kerrigan D; Pommier Y
    Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
    Del Bino G; Darzynkiewicz Z
    Cancer Res; 1991 Feb; 51(4):1165-9. PubMed ID: 1997159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine.
    Ferguson LR; Whiteside G; Holdaway KM; Baguley BC
    Environ Mol Mutagen; 1996; 27(4):255-62. PubMed ID: 8665870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.